High affinity antibodies against HMGB1 and methods of use thereof
Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
1. An isolated antibody that specifically binds a human HMGB1 polypeptide, wherein said antibody binds said human HMGB1 polypeptide with a dissociation constant (K d ) of equal to or less than 39 nM, wherein said antibody comprises:
a) a light chain variable region from the antibody G4, SEQ ID NO: 17, and a heavy chain variable region; or
b) a heavy chain variable region from the antibody G4, SEQ ID NO: 19, and a light chain variable region; or
c) a light chain variable region having the 3 CDRs of the light chain of the antibody G4, SEQ ID NO: 17, and a heavy chain variable region having the 3 CDRs of the heavy chain of the antibody G4, SEQ ID NO: 19.
2. The antibody claim 1 , wherein said antibody binds said human HMGB1 polypeptide with a dissociation constant (K d ) between 22 nM and 39 nM.
3. The antibody of claim 1 , wherein said antibody specifically binds a polypeptide comprising SEQ ID NO: 28.
4. The antibody of claim 1 , wherein said antibody specifically binds a polypeptide consisting of SEQ ID NO: 28.
5. The antibody of claim 1 , wherein said antibody comprises a light chain variable region having the 3 CDRs of the light chain of the antibody G4, SEQ ID NO: 17, and a heavy chain variable region having the 3 CDRs of the heavy chain of the antibody G4, SEQ ID NO: 19.
6. The antibody of claim 1 or 5 , wherein said antibody is a selected from the group consisting of: a monoclonal antibody, a humanized antibody; a chimeric antibody; a single-chain Fv (scFv); an Fab fragment; an F(ab′) fragment; and a synthetic antibody.
7. The antibody of claim 1 , 2 , 3 , 4 , 6 , or 5 wherein said antibody is a human antibody or an antigenic binding fragment thereof.
8. The antibody of claim 1 , wherein said antibody has a pI of between 6.5 and 9.5.
9. The antibody of claim 1 , wherein said antibody has a Tm of between 65 degrees Celsius and 95 degrees Celsius.
10. The antibody of claim 7 , wherein said antibody inhibits the release of a proinflammatory cytokine from a vertebrate cell treated with HMG1 polypeptide.
11. The antibody of claim 1 , wherein said antibody when administered to a rodent is at least 30% protective in at least one rodent arthritis model.
12. The antibody of claim 11 , wherein the rodent arthritis model is selected from the group consisiting of the mouse passive collagen-induced arthritis model, the mouse active collagen-induced arthritis model and the rat adjuvant-induced arthritis model.
13. An antibody composition comprising the antibody of claim 1 or 5 in a pharmaceutically acceptable excipeint.
14. A method for treating rheumatoid arthritis comprising administering a therapeutically effective amount of at least one antibody of claim 7 .
15. An antibody comprising a light chain variable region from the antibody G4, SEQ ID NO: 17 and a heavy chain variable region from the antibody G4, SEQ ID NO:19.
16. The antibody of claim 6 , wherein said antibody is a human antibody or an antigenic binding fragment thereof.